Shareholder Alert: Wisconsin firm Ademi LLP investigates whether Natus Medical Incorporated has obtained a Fair Price in its transaction with ArchiMed

MILWAUKEE, April 18, 2022 /PRNewswire/ -- Ademi LLP is investigating Natus (NASDAQ:NTUS) for possible breaches of fiduciary duty and other violations of law in its transaction with ArchiMed. 

Click here to learn how to join the action: https://www.ademilaw.com/case/natus-medical-incorporated or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Natus's financial outlook and prospects are excellent and yet Natus shareholders will receive only $33.50 per share. The transaction agreement unreasonably limits competing bids for Natus by prohibiting solicitation of further bids, and imposing a significant penalty if Natus accepts a superior bid. Natus insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Natus's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Natus.

If you own Natus common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/natus-medical-incorporated.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP